Makers Laboratories Limited, a pharmaceutical and chemical manufacturing company, has reported mixed financial results for the second quarter of fiscal year 2026. The company's standalone performance showed a net loss despite revenue growth, while its consolidated results demonstrated a profit.

Standalone Performance

For the quarter ended September 30, 2025, Makers Laboratories reported:

The company's standalone revenue from operations increased by 34.7% year-over-year to ₹1,372.68 crore. However, despite this growth, Makers Laboratories reported a net loss of ₹6.18 crore for the quarter, compared to a profit of ₹5.85 crore in the same period last year.

Half-Year Standalone Results

For the half-year period ended September 30, 2025:

The company's half-year revenue showed a 10.8% increase, but it reported a significant net loss of ₹70.86 crore compared to a profit in the previous year.

Consolidated Performance

On a consolidated basis, which includes the performance of its subsidiary, Resonance Specialties Limited, the company reported:

The consolidated results show a 16.8% increase in revenue from operations, but a 41.9% decrease in net profit compared to the same quarter last year.

Segment Performance

Makers Laboratories operates in two segments:

1. Pharmaceutical
2. Chemical Manufacturing

The chemical manufacturing segment remained profitable, while the pharmaceutical segment reported a loss for the quarter.

Balance Sheet Highlights

As of September 30, 2025, the company's consolidated balance sheet showed:

• Total Assets: ₹14,794.82 crore
• Total Equity: ₹7,050.59 crore
• Non-controlling Interest: ₹4,468.60 crore

Conclusion

Makers Laboratories Limited's Q2 FY26 results present a mixed picture. While the company has achieved revenue growth both on a standalone and consolidated basis, profitability remains a concern, especially in its standalone operations. The chemical manufacturing segment continues to contribute positively to the consolidated results, offsetting some of the challenges faced in the pharmaceutical segment.

Makers Laboratories Ltd has announced its financial results for the first quarter, showcasing a significant improvement in performance and a return to profitability.

Revenue Growth

The company reported a total income from operations of Rs. 3,500.10 lakhs for Q1, marking an 18.3% increase from Rs. 2,959.17 lakhs in the same quarter of the previous year. This substantial growth in revenue demonstrates the company's strong market position and effective business strategies.

Profitability Turnaround

Makers Laboratories has shown a remarkable turnaround in profitability:

The company's return to profitability is a significant achievement, particularly in light of the challenging economic environment.

Earnings Per Share

The earnings per share (EPS) for Q1 stood at Rs. 0.74, compared to a loss per share of Rs. 1.67 in the same quarter of the previous year. This positive EPS reflects the company's improved financial health and operational efficiency.

Standalone Performance

On a standalone basis, while the company still reported a loss before tax of Rs. 29.95 lakhs, it represents a substantial improvement from the Rs. 123.54 lakhs loss in the previous year's corresponding quarter.

Capital Structure

The equity share capital of Makers Laboratories remained unchanged at Rs. 590.04 lakhs, indicating stability in the company's capital structure.

Makers Laboratories Ltd's strong performance in Q1 demonstrates its resilience and ability to navigate challenging market conditions. The significant revenue growth and return to profitability are positive indicators for the company's future prospects. Investors and stakeholders will likely be encouraged by these results as the company continues to focus on sustainable growth and improved operational efficiency.